Legend Biotech Q3 revenue rises 32% to $359.5 million as Carvykti sales jump 36%
Rallies.ai · · AI-summarised by FinFlash
Legend Biotech reported third-quarter revenue up 32% to $359.5 million and adjusted net income of $55.6 million, swinging from an adjusted loss of Sustained Carvykti growth supports Legend and the CAR-T segment, and adds to Johnson & Johnson's oncology momentum. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context